ArticleScientific reports2025
Protective effect of dexpanthenol in tacrolimus-induced nephrotoxicity in rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dexpanthenol Attenuates High Fructose Corn Syrup-Induced Brain Injury by Modulating Oxidative Stress, Neuroinflammation, Apoptotic Signaling and Amyloidogenic Gene Expression.Molecular neurobiology · 2026Article
- Protective effects of dexpanthenol on experimental colitis in young rats: modulation of p53/BAX/BCL2 and RIPK1/RIPK3/MLKL signaling with anti-inflammatory activity.Pediatric research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Organ transplantation extends life expectancy; however, tacrolimus, a key immunosuppressant, carries risks of nephrotoxicity. This study explores dexpanthenol's potential to protect against tacrolimus-induced nephrotoxicity. This study was conducted using 30 male Wistar-Albino rats (aged 4 months, weighing 250-300 g), randomly divided into four groups. The control group received 0.5 cc of saline solution (SF) once daily, the TAC group received 0.4 mg/kg tacrolimus, the DEX group received 500 mg/kg dexpanthenol, and the TAC + DEX group received 0.4 mg/kg tacrolimus and 500 mg/kg dexpanthenol intraperitoneally. Biochemical parameters and kidney damage were assessed on day 14, with tissues examined by blinded pathologists using hematoxylin-eosin staining.The effects of tacrolimus on oxidative balance and the potential protective properties of dexpanthenol were investigated. Statistical analyses were performed using SPSS 20.0 software, with a p-value of < 0.05 considered significant. No significant differences were found between the groups for TAS (p = 0.827), TOS (p = 0.596), OSI (p = 0.575), SOD (p = 0.952), and NO (p = 0.365) values. However, significant differences were observed in IL-6 (p = 0.008), CRP (p = 0.034), TNF-alpha (p = 0.014), TGF-β (p = 0.012), MDA (p = 0.001), urea(p = 0.005), and creatinine (p = 0.002) levels. Pathological examination revealed significant findings in Bowman capsule expansion (p = 0.003), the presence of mitosis (p = 0.005), vasa recta leukocyte infiltration (VRLI) (p = 0.007), tubular regeneration (p = 0.004), tubular dilation (p = 0.003), tubular necrosis (p = 0.048), cast formation (p = 0.020), and loss of the brush border (p = 0.019). The only parameter without a significant difference among the groups was interstitial inflammation (p = 0.559). This study shows that dexpanthenol provides limited protection against tacrolimus-induced nephrotoxicity and requires further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.